VAL Stock Overview
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ValiRx plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.035 |
| 52 Week High | UK£0.15 |
| 52 Week Low | UK£0.033 |
| Beta | 0.63 |
| 1 Month Change | -10.39% |
| 3 Month Change | -33.01% |
| 1 Year Change | -66.34% |
| 3 Year Change | -83.17% |
| 5 Year Change | -93.35% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| VAL | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -4.8% | -1.9% | -0.9% |
| 1Y | -66.3% | -30.5% | -1.8% |
Return vs Industry: VAL underperformed the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: VAL underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| VAL volatility | |
|---|---|
| VAL Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: VAL's share price has been volatile over the past 3 months.
Volatility Over Time: VAL's weekly volatility has decreased from 12% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 8 | Suzy Dilly | www.valirx.com |
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company’s lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19.
ValiRx plc Fundamentals Summary
| VAL fundamental statistics | |
|---|---|
| Market cap | UK£4.57m |
| Earnings (TTM) | -UK£2.41m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.9x
P/E RatioIs VAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VAL income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£2.41m |
| Earnings | -UK£2.41m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.7% |
How did VAL perform over the long term?
See historical performance and comparison